Skip to content
2000
Volume 20, Issue 2
  • ISSN: 1574-8928
  • E-ISSN: 2212-3970

Abstract

Objective

Current cisplatin (CDDP) resistance remains a major challenge in the treatment of advanced gastric cancer. To address the issue of drug resistance, we explored the regulatory functions of PDZ and LIM structural domain protein 1 (PDLIM1) in CDDP chemotherapy for gastric cancer.

Methods

In this study, we analyzed PDLIM1 expression and prognosis using bioinformatics on publicly available data. PDLIM1 expression in a gastric mucosal epithelial cell line (GSE-1), CDDP-sensitive (SGC7901, BGC823) and CDDP-resistant gastric cancer cells was detected by RT-qPCR and Western blotting. Cell proliferative capacity was assessed by knockdown of PDLIM1 and overexpression of PDLIM1 in cells administered in combination with cisplatin, and apoptotic levels were measured by CCK-8 and colony formation assay and by flow cytometry. Expression of breast cancer susceptibility gene 1 (BRCA1) and γH2AX was determined by Western blotting or immunofluorescence staining.

Results

Downregulation of PDLIM1 was found in tumor tissues and cells, which was associated with poor clinical outcomes. Knockdown of PDLIM1 enhanced proliferation and attenuated apoptosis in gastric cancer cells. In addition, the therapeutic effects of CDDP on proliferation, apoptosis, and DNA damage repair were attenuated by PDLIM1 deletion.PDLIM1 expression was downregulated in CDDP-resistant tumor cells. Overexpression of PDLIM1 overcomes CDDP resistance in tumor cells as BRCA1 expression decreases and γH2AX expression increases.

Conclusion

Our findings demonstrate that PDLIM1 enables to alleviate gastric cancer progression and resistance to cisplatin impeding DNA damage repair.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928307544240502064448
2024-05-22
2025-07-25

  • From This Site

    /content/journals/pra/10.2174/0115748928307544240502064448
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. CatsA. JansenE.P.M. van GriekenN.C.T. SikorskaK. LindP. NordsmarkM. Meershoek-Klein KranenbargE. BootH. TripA.K. SwellengrebelH.A.M. van LaarhovenH.W.M. PutterH. van SandickJ.W. van Berge HenegouwenM.I. HartgrinkH.H. van TinterenH. van de VeldeC.J.H. VerheijM. Van CoevordenF. VanhoutvinS. HulshofM.C.C.M. LoosveldO.J.L. Ten TijeA.B.J. ErdkampF.L.G. WarmerdamF.A.R.M. Van der PeetD.L. VerheulH.M.W. BoermaD. LosM. SlotA. HoutsmaD. PortieljeJ.E.A. BlaisseR.J.B. Spillenaar BilgenE.J. PoléeM.B. GeenenM.M. BraakJ.P.B.M. NeelisK.J. SlingerlandM. JansenR.L.H. BuijsenJ. BeekerA. EijsboutsQ.A.J. Van RielJ.M.G.H. RozemaT. Van SpronsenD.J. Meerum TerwogtJ.M. TanisB.C. Van der Torren-ConzeA.M.E. Van HilligersbergR. KoopmanM. Den BoerM.O. CreemersG-J. Van der SangenM. RentinckM.E.M. Van den BergH.P. JonkersG.J.P.M. GrootenboersD. VulinkA.J.E. HovengaS. Van der MijleH.C.J. BaarsA. HaringhuizenA.W. AppelsM.I.E. RietbroekR.C. HendriksenE.M. LegdeurM-C.J.C. Ten Bokkel HuininkD. Van DobbenburghO.A. SmitJ.M. Van BochoveA. VeldhuisG-J. MullerE.W. BonenkampJ.H.J. BraamP.M. De BoerJ. Van HalterenH.K. ValsterF.A.A. ImholzA.L.T. Van DijkM.A. Van der GaastA. OttenJ.H-M.M.B. CehaH.M. GlimeliusB. LagerbäckC. PermanM. JohnssonA. BorgD. NielsenN.H. PiwowarA. ElmlundM. HörbergH. EdlundP. JohanssonB. FlygareP. JespersenM.L. CRITICS investigators Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial.Lancet Oncol.201819561662810.1016/S1470‑2045(18)30132‑329650363
     [Google Scholar]
  2. IshigamiH. FujiwaraY. FukushimaR. NashimotoA. YabusakiH. ImanoM. ImamotoH. KoderaY. UenosonoY. AmagaiK. KadowakiS. MiwaH. YamaguchiH. YamaguchiT. MiyajiT. KitayamaJ. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial.J. Clin. Oncol.201836191922192910.1200/JCO.2018.77.861329746229
     [Google Scholar]
  3. KangY.K. ChinK. ChungH.C. KadowakiS. OhS.C. NakayamaN. LeeK.W. HaraH. ChungI.J. TsudaM. ParkS.H. HosakaH. HironakaS. MiyataY. RyuM.H. BabaH. HyodoI. BangY.J. BokuN. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): A randomised, open-label, phase 3 trial.Lancet Oncol.20202181045105610.1016/S1470‑2045(20)30315‑632682457
     [Google Scholar]
  4. MondacaS. MargolisM. Sanchez-VegaF. JonssonP. RichesJ.C. KuG.Y. HechtmanJ.F. TuvyY. BergerM.F. ShahM.A. KelsenD.P. IlsonD.H. YuK. GoldbergZ. EpsteinA.S. DesaiA. ChungV. ChouJ.F. CapanuM. SolitD.B. SchultzN. JanjigianY.Y. Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.Gastric Cancer201922235536210.1007/s10120‑018‑0861‑730088161
     [Google Scholar]
  5. LuZ. ZhangX. LiuW. LiuT. HuB. LiW. FanQ. XuJ. XuN. BaiY. PanY. XuQ. BaiW. XiaL. GaoY. WangW. ShuY. ShenL. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer.Gastric Cancer201821578279110.1007/s10120‑018‑0809‑y29488121
     [Google Scholar]
  6. OkabeH. HataH. HosogiH. UedaS. OtaS. KinjoY. HoshinoN. HisamoriS. TsunodaS. ObamaK. SakaiY. Kyoto University Surgical Oncology Group (KUSOG) A phase 2 study of induction chemotherapy using docetaxel, cisplatin, and S-1 for gastric cancer with peritoneal metastasis (KUGC06).Ann. Surg. Oncol.20192661779178610.1245/s10434‑019‑07229‑730767179
     [Google Scholar]
  7. WangJ. XuR. LiJ. BaiY. LiuT. JiaoS. DaiG. XuJ. LiuY. FanN. ShuY. BaY. MaD. QinS. ZhengL. ChenW. ShenL. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.Gastric Cancer201619123424410.1007/s10120‑015‑0457‑425604851
     [Google Scholar]
  8. WangM LiW LiuP Gamma-aminobutyric acid receptor antagonist composition and application of gamma-aminobutyric acid receptor antagonist composition in preparation of medicine for treating gastric cancer.C.N. Patent 202311514922023
  9. LiM. ZhangH.Y. ZhangR.G. MFAP2 enhances cisplatin resistance in gastric cancer cells by regulating autophagy.PeerJ202311e1544110.7717/peerj.1544137304872
     [Google Scholar]
  10. BauerK. KratzerM. OtteM. de QuintanaK.L. HagmannJ. ArnoldG.J. EckerskornC. LottspeichF. SiessW. Human CLP36, a PDZ-domain and LIM-domain protein, binds to α-actinin-1 and associates with actin filaments and stress fibers in activated platelets and endothelial cells.Blood200096134236424510.1182/blood.V96.13.423611110697
     [Google Scholar]
  11. AhnB.Y. Saldanha-GamaR F G. RahnJ.J. HaoX. ZhangJ. DangN-H. AlshehriM. RobbinsS.M. SengerD.L. Glioma invasion mediated by the p75 neurotrophin receptor (p75NTR/CD271) requires regulated interaction with PDLIM1.Oncogene201635111411142210.1038/onc.2015.19926119933
     [Google Scholar]
  12. ValleniusT. ScharmB. VesikansaA. LuukkoK. SchäferR. MäkeläT.P. The PDZ-LIM protein RIL modulates actin stress fiber turnover and enhances the association of α-actinin with F-actin.Exp. Cell Res.2004293111712810.1016/j.yexcr.2003.09.00414729062
     [Google Scholar]
  13. HuangZ. ZhouJ.K. WangK. ChenH. QinS. LiuJ. LuoM. ChenY. JiangJ. ZhouL. ZhuL. HeJ. LiJ. PuW. GongY. LiJ. YeQ. DongD. HuH. ZhouZ. DaiL. HuangC. WeiX. PengY. PDLIM1 inhibits tumor metastasis through activating hippo signaling in hepatocellular carcinoma.Hepatology20207151643165910.1002/hep.3093031509262
     [Google Scholar]
  14. ChenH.N. YuanK. XieN. WangK. HuangZ. ChenY. DouQ. WuM. NiceE.C. ZhouZ.G. HuangC. PDLIM1 stabilizes the E-cadherin/β-catenin complex to prevent epithelial–mesenchymal transition and metastatic potential of colorectal cancer cells.Cancer Res.20167651122113410.1158/0008‑5472.CAN‑15‑196226701804
     [Google Scholar]
  15. ZhuX. ChenL. LiuL. NiuX. EMT-mediated acquired EGFR-TKI resistance in NSCLC: Mechanisms and strategies.Front. Oncol.20199104410.3389/fonc.2019.0104431681582
     [Google Scholar]
  16. LiuZ. ZhanY. TuY. ChenK. LiuZ. WuC. PDZ and LIM domain protein 1(PDLIM1)/CLP36 promotes breast cancer cell migration, invasion and metastasis through interaction with α-actinin.Oncogene201534101300131110.1038/onc.2014.6424662836
     [Google Scholar]
  17. LiL.M. LuoF.J. SongX. MicroRNA-370-3p inhibits cell proliferation and induces chronic myelogenous leukaemia cell apoptosis by suppressing PDLIM1/Wnt/β-catenin signalling.Neoplasma202067350951810.4149/neo_2020_190612N50631986893
     [Google Scholar]
  18. EmensL.A. MolineroL. LoiS. RugoH.S. SchneeweissA. DiérasV. IwataH. BarriosC.H. NechaevaM. Nguyen-DucA. ChuiS.Y. HusainA. WinerE.P. AdamsS. SchmidP. Atezolizumab and nab -paclitaxel in advanced triple-negative breast cancer: Biomarker evaluation of the IMpassion130 study.J. Natl. Cancer Inst.202111381005101610.1093/jnci/djab00433523233
     [Google Scholar]
  19. de BonoJ.S. MehraN. ScagliottiG.V. CastroE. DorffT. StirlingA. StenzlA. FlemingM.T. HiganoC.S. SaadF. ButtiglieroC. van OortI.M. LairdA.D. MataM. ChenH.C. HealyC.G. CzibereA. FizaziK. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): An open-label, phase 2 trial.Lancet Oncol.20212291250126410.1016/S1470‑2045(21)00376‑434388386
     [Google Scholar]
  20. JavleM. Shacham-ShmueliE. XiaoL. VaradhacharyG. HalpernN. FogelmanD. BoursiB. UrubaS. MargalitO. WolffR.A. GolanT. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants.JAMA Oncol.20217569369910.1001/jamaoncol.2021.000633662100
     [Google Scholar]
  21. SmythE.C. WotherspoonA. PeckittC. GonzalezD. Hulkki-WilsonS. EltahirZ. FassanM. RuggeM. ValeriN. OkinesA. HewishM. AllumW. StenningS. NankivellM. LangleyR. CunninghamD. Mismatch repair deficiency, microsatellite instability, and survival.JAMA Oncol.2017391197120310.1001/jamaoncol.2016.676228241187
     [Google Scholar]
  22. YangY. QuS. LiJ. HuC. XuM. LiW. ZhouT. ShenL. WuH. LangJ. HuG. LuoZ. FuZ. QuS. FengW. ChenX. LinS. ZhangW. LiX. SunY. LinZ. LinQ. LeiF. LongJ. HongJ. HuangX. ZengL. WangP. HeX. ZhangB. YangQ. ZhangX. ZouJ. FangW. ZhangL. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): A multicentre, randomised, double-blind, phase 3 trial.Lancet Oncol.20212281162117410.1016/S1470‑2045(21)00302‑834174189
     [Google Scholar]
  23. JohnsonM.L. ChoB.C. LuftA. Alatorre-AlexanderJ. GeaterS.L. LaktionovK. KimS.W. UrsolG. HusseinM. LimF.L. YangC.T. AraujoL.H. SaitoH. ReinmuthN. ShiX. PooleL. PetersS. GaronE.B. MokT. POSEIDON investigators Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: The phase III POSEIDON study.J. Clin. Oncol.20234161213122710.1200/JCO.22.0097536327426
     [Google Scholar]
  24. PfisterC. GravisG. FléchonA. SouliéM. GuyL. LaguerreB. MottetN. JolyF. AlloryY. HarterV. CulineS. VESPER Trial Investigators Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: Chemotherapy toxicity and pathological responses.Eur. Urol.202179221422110.1016/j.eururo.2020.08.02432868138
     [Google Scholar]
  25. GuigayJ. AupérinA. FayetteJ. Saada-BouzidE. LafondC. TabernaM. GeoffroisL. MartinL. CapitainO. CupissolD. CastanieH. VansteeneD. SchafhausenP. JohnsonA. EvenC. SireC. DuplombS. EvrardC. DelordJ.P. LaguerreB. ZanettaS. Chevassus-ClémentC. FraslinA. LouatF. SinigagliaL. KeilholzU. BourhisJ. MesiaR. Baba-HamedN. BabinE. BeraG. Betrian-LagardeS. BlotE. BompasE. BorelC. BouchekouaM. Bozec Le MoalL. BruyasA. CalaisG. CarpiucI. ChapetS. ChatellierT. ChauffertB. CheliS. ClatotF. CojocarasuO. CornellyA. CoutteA. DallozP. DarloyF. DelhommeauM. De RaucourtD. DebelleixC. DebourdeauP. Dillies-LegrainA.F. DoP. Dubos-ArvisC. DucoulombierA. El KouriC. FalkowskiS. FerrandF-R. GatineauM. GervaisR. GrasL. GuilletP. HasbiniA. HenaultS. Herrera GomezR.G. HuguetF. KaminskyM.C. LagrangeA. Lavau-DenesS. Le CaerH. Le FollC. LefebvreG. LinotB. LopezQ. LortholaryA. MatiasM. Mayache-BadisL. MinneF. MollonD. NeidhardtE.M. PavilletJ. PeyradeF. PointreauY. RameeJ-F. RaucheC. RichardS. RizzoC. RollandF. SchlurmannF. StefaniL. TassyL. TaziY. TheryJ-C. Torti El ZeinF. ToullecC. TouraniJ-M. ToussaintP. VanbockstaelJ. VauleonE. ViretF. WalerS. AtzpodienJ. BehrensC. BuschC.J. DietzA. FeldmannG. FietkauR. GranizkaT. GreweJ. Guntinas-LichinusO. Hadler-MikeschK. HahnD. InhesternJ. KellnerK. KlinghammerK. KronenbergerR. Luedtke-HeckenkampK. OchsenreitherS. OtrembaB. PeukerC.A. PirlichM. RothmannF. TomettenM. WohlfarthS. ZebrallaV. ZipfelM. Adansa KleinJ.C. ArrazubiV. Caballero DaroquiJ. CasteloB. Cirauqui CirauquiB. Cruz HernandezJ.J. GallegoO. Iglesias DocampoL.C. Lopez PousaA. Martinez Del PradoM. Martinez-TruferoJ. Pastor BorgononM. Perez RuizE. Quiroga GarciaV. Rubio CasadevallJ. Vazquez FernandezS. GORTEC AIO TTCC, and UniCancer Head and Neck groups Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): A multicentre, open-label, randomised, phase 2 trial.Lancet Oncol.202122446347510.1016/S1470‑2045(20)30755‑533684370
     [Google Scholar]
  26. Rodríguez-AbreuD. PowellS.F. HochmairM.J. GadgeelS. EstebanE. FelipE. SperanzaG. De AngelisF. DómineM. ChengS.Y. BischoffH.G. PeledN. ReckM. HuiR. GaronE.B. BoyerM. KurataT. YangJ. PietanzaM.C. SouzaF. GarassinoM.C. Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: Protocol-specified final analysis from KEYNOTE-189.Ann. Oncol.202132788189510.1016/j.annonc.2021.04.00833894335
     [Google Scholar]
  27. Gebre-MedhinM. BrunE. EngströmP. Haugen CangeH. Hammarstedt-NordenvallL. ReizensteinJ. NymanJ. AbelE. FrieslandS. SjödinH. CarlssonH. SöderkvistK. ThomassonM. ZackrissonB. NilssonP. ARTSCAN III: A randomized phase III study comparing chemoradiotherapy with cisplatin versus cetuximab in patients with locoregionally advanced head and neck squamous cell cancer.J. Clin. Oncol.2021391384710.1200/JCO.20.0207233052757
     [Google Scholar]
  28. KissR.C. XiaF. AcklinS. Targeting DNA damage response and repair to enhance therapeutic index in cisplatin-based cancer treatment.Int. J. Mol. Sci.20212215819910.3390/ijms2215819934360968
     [Google Scholar]
  29. (a RochaCRR SilvaMM Cabral-NetoJB MenckCFM DNA repair pathways and cisplatin resistance: an intimate relationship.Clinics (Sao Paulo)2018Sep 6; 73suppl 1e478s10.6061/clinics/2018/e478s30208165
     [Google Scholar]
  30. (a RochaCRR SilvaMM Cabral-NetoJB MenckCFM DNA repair pathways and cisplatin resistance: an intimate relationship.Clinics (Sao Paulo)2018Sep 6; 73suppl 1e478s10.6061/clinics/2018/e478s30208165
     [Google Scholar]
  31. LánczkyA. GyőrffyB. Web-based survival analysis tool tailored for medical research (KMplot): Development and implementation.J. Med. Internet Res.2021237e2763310.2196/2763334309564
     [Google Scholar]
  32. ZhaoJ. ZhongS. NiuX. JiangJ. ZhangR. LiQ. The MHC class I-LILRB1 signalling axis as a promising target in cancer therapy.Scand. J. Immunol.2019905e1280410.1111/sji.1280431267559
     [Google Scholar]
  33. QiuX.T. SongY.C. LiuJ. WangZ.M. NiuX. HeJ. Identification of an immune-related gene-based signature to predict prognosis of patients with gastric cancer.World J. Gastrointest. Oncol.202012885787610.4251/wjgo.v12.i8.85732879664
     [Google Scholar]
  34. KongX. FuM. NiuX. JiangH. Comprehensive analysis of the expression, relationship to immune infiltration and prognosis of TIM-1 in cancer.Front. Oncol.202010108610.3389/fonc.2020.0108633014768
     [Google Scholar]
  35. WangX. ChengG. MiaoY. QiuF. BaiL. GaoZ. HuangY. DongL. NiuX. WangX. LiY. TangH. XuY. SongX. Piezo type mechanosensitive ion channel component 1 facilitates gastric cancer omentum metastasis.J. Cell. Mol. Med.20212542238225310.1111/jcmm.1621733439514
     [Google Scholar]
  36. JhaveriK.L. WangX.V. MakkerV. LuohS.W. MitchellE.P. ZwiebelJ.A. SharonE. GrayR.J. LiS. McShaneL.M. RubinsteinL.V. PattonD. WilliamsP.M. HamiltonS.R. ConleyB.A. ArteagaC.L. HarrisL.N. O’DwyerP.J. ChenA.P. FlahertyK.T. Corrigendum to ‘Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH trial (EAY131) subprotocol Q’: [Annals of Oncology 30 (2019) 1821-1830].Ann. Oncol.2021328106810.1016/j.annonc.2021.05.79734099371
     [Google Scholar]
  37. KatoK. SatohT. MuroK. YoshikawaT. TamuraT. HamamotoY. ChinK. MinashiK. TsudaM. YamaguchiK. MachidaN. EsakiT. GotoM. KomatsuY. NakajimaT.E. SugimotoN. YoshidaK. OkiE. NishinaT. TsujiA. FujiiH. KuniedaK. SaitohS. OmuroY. AzumaM. IwamotoY. TakuK. FushidaS. ChenL.T. KangY.K. BokuN. A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2).Gastric Cancer201922234435410.1007/s10120‑018‑0899‑630506519
     [Google Scholar]
  38. QiuC. DuanY. WangB. ShiJ. WangP. YeH. DaiL. ZhangJ. WangX. Serum Anti-PDLIM1 autoantibody as diagnostic marker in ovarian cancer.Front. Immunol.20211269831210.3389/fimmu.2021.69831234489945
     [Google Scholar]
  39. WangH. TangH. FangY. TanL. YinJ. ShenY. ZengZ. ZhuJ. HouY. DuM. JiaoJ. JiangH. GongL. LiZ. LiuJ. XieD. LiW. LianC. ZhaoQ. ChenC. ZhengB. LiaoY. LiK. LiH. WuH. DaiL. ChenK.N. Morbidity and mortality of patients who underwent minimally invasive esophagectomy after neoadjuvant chemoradiotherapy vs neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma.JAMA Surg.2021156544445110.1001/jamasurg.2021.013333729467
     [Google Scholar]
  40. LeeN.Y. FerrisR.L. PsyrriA. HaddadR.I. TaharaM. BourhisJ. HarringtonK. ChangP.M.H. LinJ.C. RazaqM.A. TeixeiraM.M. LöveyJ. ChamoisJ. RuedaA. HuC. DunnL.A. DvorkinM.V. De BeukelaerS. PavlovD. ThurmH. CohenE. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: A randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.Lancet Oncol.202122445046210.1016/S1470‑2045(20)30737‑333794205
     [Google Scholar]
  41. SugimuraK. MiyataH. TanakaK. MakinoT. TakenoA. ShiraishiO. MotooriM. YamasakiM. KimuraY. HiraoM. FujitaniK. YasudaT. MoriM. EguchiH. YanoM. DokiY. Multicenter randomized phase 2 trial comparing chemoradiotherapy and docetaxel plus 5-fluorouracil and cisplatin chemotherapy as initial induction therapy for subsequent conversion surgery in patients with clinical T4b esophageal cancer.Ann. Surg.20212746e465e47210.1097/SLA.000000000000456433065643
     [Google Scholar]
  42. ChenL. NiuX. QiaoX. LiuS. MaH. ShiX. HeX. ZhongM. Characterization of interplay between autophagy and ferroptosis and their synergistical roles on manipulating immunological tumor microenvironment in squamous cell carcinomas.Front. Immunol.20221273903910.3389/fimmu.2021.73903935185859
     [Google Scholar]
  43. LowH.B. WongZ.L. WuB. KongL.R. PngC.W. ChoY.L. LiC.W. XiaoF. XinX. YangH. LooJ.M. LeeF.Y.X. TanI.B.H. DasGuptaR. ShenH.M. SchwarzH. GascoigneN.R.J. GohB.C. XuX. ZhangY. DUSP16 promotes cancer chemoresistance through regulation of mitochondria-mediated cell death.Nat. Commun.2021121228410.1038/s41467‑021‑22638‑733863904
     [Google Scholar]
  44. YamadaY. BokuN. MizusawaJ. IwasaS. KadowakiS. NakayamaN. AzumaM. SakamotoT. ShitaraK. TamuraT. ChinK. HataH. NakamoriM. HaraH. YasuiH. KatayamaH. FukudaH. YoshikawaT. SasakoM. TerashimaM. Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): An open-label, phase 3, randomised controlled trial.Lancet Gastroenterol. Hepatol.20194750151010.1016/S2468‑1253(19)30083‑431101534
     [Google Scholar]
  45. FujitaniK. YangH.K. MizusawaJ. KimY.W. TerashimaM. HanS.U. IwasakiY. HyungW.J. TakaganeA. ParkD.J. YoshikawaT. HahnS. NakamuraK. ParkC.H. KurokawaY. BangY.J. ParkB.J. SasakoM. TsujinakaT. REGATTA study investigators Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.Lancet Oncol.201617330931810.1016/S1470‑2045(15)00553‑726822397
     [Google Scholar]
  46. LeongT. SmithersB.M. HaustermansK. MichaelM. GebskiV. MillerD. ZalcbergJ. BoussioutasA. FindlayM. O’ConnellR.L. VerghisJ. WillisD. KronT. CrainM. MurrayW.K. LordickF. SwallowC. DarlingG. SimesJ. WongR. TOPGEAR: A randomized, phase III trial of perioperative ecf chemotherapy with or without preoperative chemoradiation for resectable gastric cancer: Interim results from an international, intergroup trial of the AGITG, TROG, EORTC and CCTG.Ann. Surg. Oncol.20172482252225810.1245/s10434‑017‑5830‑628337660
     [Google Scholar]
  47. LeeJ. LimD.H. KimS. ParkS.H. ParkJ.O. ParkY.S. LimH.Y. ChoiM.G. SohnT.S. NohJ.H. BaeJ.M. AhnY.C. SohnI. JungS.H. ParkC.K. KimK.M. KangW.K. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: The ARTIST trial.J. Clin. Oncol.201230326827310.1200/JCO.2011.39.195322184384
     [Google Scholar]
  48. SmythE.C. GambardellaV. CervantesA. FleitasT. Checkpoint inhibitors for gastroesophageal cancers: Dissecting heterogeneity to better understand their role in first-line and adjuvant therapy.Ann. Oncol.202132559059910.1016/j.annonc.2021.02.00433609722
     [Google Scholar]
  49. LozinskiM. BowdenN.A. GravesM.C. FayM. TooneyP.A. DNA damage repair in glioblastoma: Current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.Cell Oncol.202144596198110.1007/s13402‑021‑00613‑034057732
     [Google Scholar]
  50. PuppeJ. OpdamM. SchoutenP.C. JóźwiakK. LipsE. SeversonT. van de VenM. BrambillascaC. BouwmanP. van TellingenO. BernardsR. WesselingJ. EichlerC. ThangarajahF. MalterW. PandeyG.K. OzretićL. CaldasC. van LohuizenM. HauptmannM. RhiemK. HahnenE. ReinhardtH.C. BüttnerR. MallmannP. Schömig-MarkiefkaB. SchmutzlerR. LinnS. JonkersJ. EZH2 is overexpressed in BRCA1 -like breast tumors and predictive for sensitivity to high-dose platinum-based chemotherapy.Clin. Cancer Res.201925144351436210.1158/1078‑0432.CCR‑18‑402431036541
     [Google Scholar]
  51. RahmanianN. ShokrzadehM. EskandaniM. Recent advances in γH2AX biomarker-based genotoxicity assays: A marker of DNA damage and repair.DNA Repair202110810324310.1016/j.dnarep.2021.10324334710661
     [Google Scholar]
/content/journals/pra/10.2174/0115748928307544240502064448
Loading
PDLIM1 Inhibits Chemoresistance by Blocking DNA Damage Repair in Gastric Cancer
Recent Patents on Anti-Cancer Drug Discovery 20, 260 (2025); https://doi.org/10.2174/0115748928307544240502064448
/content/journals/pra/10.2174/0115748928307544240502064448
/content/journals/pra/10.2174/0115748928307544240502064448
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): BRCA1; cisplatin resistance; DNA damage repair; Gastric cancer; PDLIM1; γH2AX

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test